CD274 and non-small cell lung carcinoma: Recently, immune checkpoint inhibitors (ICIs) have shown significant promise, with anti-PD-1/PD-L1 immunotherapy as a typical case, which has improved progression-free survival (PFS) and overall survival (OS) for advanced NSCLC [2–4].